New data for KidneyIntelX
("Renalytix" or the "Company")
KidneyIntelXTM Enables Monitoring of SGLT2 Inhibitor Therapy Response
and Corresponding Risk Reduction Over Time
Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations
These results will be further evaluated through a growing body of real-world evidence and clinical effectiveness data driven by the KidneyIntelX multi-institutional study network in over 6,000 patients. The network is assessing the ability of KidneyIntelX to 1) to appropriately risk stratify patients in early stage (stage 1, 2 and 3) kidney disease; 2) help guide the optimal medication regimen based on individualized risk assessment; and 3) monitor therapeutic response and kidney health using repeat testing over time. KidneyIntelX is being deployed to manage DKD populations beginning at primary care level in partnership with large health care systems including the
The oral presentation titled, "Longitudinal Changes in
These data are the second output in a series of analyses of the CANVAS cohort in conjunction with
For further information, please contact:
Renalytix plc |
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About KidneyIntelX
KidneyIntelX, is a first-of-kind, bioprognosticTM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits of repeat testing with KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the